Early, intensive management of diabetes is essential to reduce the risk of diabetic complications.
Despite this, fewer than 10 per cent of Australians with diabetes are adequately treated and complication free.
Glucagon-like peptide-1 receptor agonists are a group of medicines that provide robust glycaemic control and weight loss benefits. This makes them an ideal choice for intensifying treatment in many people with type 2 diabetes.
Guild Learning and Development has partnered with Novo Nordisk in the development of a new online module titled Ozempic® (semaglutide): a once-weekly GLP-1 for the management of type 2 diabetes.
The module looks at the importance of early intensification of diabetes management, and provides information on the dosing, administration and clinical use of Ozempic®.
This activity has been accredited for 1.5 hours of Group 1 CPD (or 1.5 CPD credits) suitable for inclusion in an individual pharmacist's CPD plan which can be converted to 1.5 hours of Group 2 CPD (or 3 CPD credits) upon successful completion of relevant assessment activities.
To enrol in this course please visit guilded.guild.org.au
